Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

Novo Nordisk is working with GoodRx to offer a month’s supply of Ozempic for $499, or about half the list price, for self-paying patients.  Ozempic, a drug approved for Type 2 diabetes, cardiovascular ...

The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its ...

Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

NEW YORK — Wall Street is holding near its record heights on Monday, ahead of a week likely to be dominated by updates from ...

U.S. stock futures edged lower Monday, while Treasuries gained, as traders focused on progress toward a potential peace deal for Ukraine and awaited signals from the Federal Reserve on interest rates.

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Live Updates Live Coverage Updates appear automatically as they are published. The Crowd Goes Wild for Live Nation 9:36 am ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...